



April 2017
Enrolling Physicians for March 2017

Physician	Patient Registrations	Treatment Credits	Control Credits	Total Credits	Tissue Procurement	Cancer Care Delivery Res.
Dr. Bumberry (Mercy Spfld)					2	
Dr. Carlson (Mercy Spfld)	1	1.7875		1.7875		1
Dr. Cunningham (OHA)			0.0125	0.0125		1
Dr. Dalia (Mercy Joplin)		0.5250	0.2625	0.7875		
Dr. Donegan (Mercy St. Louis)	1	1		1		
Dr. Ellis (OHA)		0.5125		0.5125		
Dr. Gillette (OHA)						1
Dr. Huq (Mercy St. Louis)	PALLAS x 2					
Dr. Lobins (Cox)	1	1.1375	0.25	1.3875		
Dr. Oza (Good Samaritan)	1		1.0125	1.0125		
Dr. Pinheiro (Mercy Spfld)					1-blood only	
Dr. Rodgers (Mercy St. Louis)	PALLAS					
Dr. Snider (Mercy Spfld)			0.0250	0.0250		3
Dr. Tiriveedhi (Mercy Spfld)			0.0125	0.0125		2
Dr. Tummala (Mercy Spfld)						1
TOTALS	4	4.9625	1.575	6.5375	2 + 1 blood	9

CRO enrollments continue to be slow. All efforts to place patients on trial is encouraged. We did obtain two Tissue & Blood specimens this month and one blood only. This gives CRO 22 of the 36 specimens needed for this year's supplement. Our CCDR enrollments (S1415CD) continue to grow. Mercy Springfield has placed 35 and CoxHealth has placed 11 participants on this trial. Each site is to enroll 52 participants to this study.

Spring 2017 CRO Steering Committee Meeting

Gary Doolittle MD, Professor of Medicine and Director of Telemedicine Services at The University of Kansas Medical Center will be our speaker for our CRO 2017 Steering Committee meeting. His presentation is entitled "Dual Immune Checkpoint Inhibition for the First-line Treatment of Metastatic Melanoma". Dr. Doolittle is a Medical Oncology and been involved in research throughout his career and is well published. Jennifer Walter, Nurse Practitioner will speak following Dr. Doolittle on "OPDIVO for Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head & Neck". Jennifer is the Immuno-Oncology Clinical Liaison for Bristol-Myers Squibb. Jennifer has experience in community medical oncology. The meeting will be held on Wednesday, May 17th at 6p at TOUCH restaurant located at 1620 E. Republic Road in Springfield. Please RSVP to (417) 269-4520 by Friday, May 12th or to Marilyn Bauer at MarilynBauer@coxhealth.com.

SWOG S1206 Profile Study

"Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery" is our profile study for April. This phase I/II partially randomized trial studies the side effects and best dose of veliparib when given together with radiation therapy, carboplatin, and paclitaxel and to see how well it works in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery. Veliparib may

stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether radiation therapy, carboplatin, and paclitaxel are more effective with or without veliparib in treating non-small cell lung cancer.

ACTIVATION OF CIRB Protocols:

New Local Protocols:

None

CIRB Protocols:

ECOG-ACRIN EA2161 A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET) - CIRB approved 2/27/2017

Study Closure through Local IRB:

GOG-0283 A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND #73969) In Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, Endometrial, or Endometriosis-Associated Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression

Closed to enrollment: 03/20/2017